3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
12
Plasma cell
3
Gastrointestinal
3
Tumor-Agnostic
2
Thoracic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Radiotherapy
137
Cyclophosphamide
132
Temozolomide
116
Doxorubicin
99
Filgrastim
68
Ifosfamide
64
Gemcitabine
58
Etoposide
55
Bevacizumab
51
Imatinib Mesylate
50
fludarabine phosphate
49
Irinotecan
46
pembrolizumab
45
Peripheral Blood Stem Cell Transplantation
45
pazopanib
43
Magnetic Resonance Spectroscopy
42
Methotrexate
40
Carboplatin
40
Busulfan
40
Vincristine
38
Surgical Procedures, Operative
37
Nivolumab
37
Melphalan
37
Cisplatin
36
Radiation
34
Blood Specimen Collection
33
Mycophenolic Acid
31
Cyclosporine
31
Docetaxel
29
Trabectedin
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Rivaroxaban
×
Sarcoma
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled